Implemented for the first time in Spain one of the defibrillators small and most of the world.

-defibrillators Ilesto family offers from 7.5 to 11.5-year

-approved to carry out magnetic resonance

Madrid, February 2013.- El Dr. Juan Gabriel Martinezresponsible for arrhythmias at the General Hospital of Alicante unit, and his team have been pioneers in Spain in the implementation of one of the resincronizadores defibrillators (CRT-D) smaller in the world, Ilesto 7 HF-T. This device, created by BIOTRONIK, is equipped with ProMRI ® technology, which allows access to examinations of MRI, tests that save millions of lives each year.

” Ilesto 7 HF-T implantable defibrillator has relevant features that could considerably facilitate the patients of cardiac resynchronization therapy and quality of life”, explains Dr. Juan Gabriel Martínez, head of the unit of arrhythmias of the General Hospital of Alicante. “We chose the Ilesto due to their long service life and because it is one of the smaller devices with defibrillators (DAIs).” Its size is similar to a pacemaker ”. This is an important point – is the doctor – because it improves the comfort of the patient and at the same time achieves optimal aesthetic results ”.

doctors in arrhythmias at the General Hospital of Alicante unit. From left to right: Dr. José Luis Ibáñez, Dr. Alicia Ibáñez, DRA. Amaya Garcia and Dr. Juan Gabriel Martinez.

Another great advantage of this scientific progress is the battery of the device. Ilesto offers patients and doctors greater longevity available, up to 11.5 years for the unicameral DAI and 7.5 years for the CRT-d device Thanks to greater longevity of the device, future spare parts number can be reduced and therefore limit the risk of complications associated with such procedures.

ProMRI ® technology, that only the company Biotronik has integrated into its latest models give and CRT-D, makes it possible that the defibrillator is approved to carry out magnetic resonance imaging. The number of patients with resincronizadores defibrillators is growing and it is estimated that 50 to 75 percent of these patients need to undergo an MRI during the useful life of your devices.(1) These tests, which provide extremely accurate images, are used on a regular basis for the diagnosis of tumors and cerebrovascular accidents. The number of images in all magnetic resonance imaging the world increased from 30 million in 2006 to around 50 million in 2010.(2)

Since patients increasingly have a longer life expectancy and often suffer co-morbidities, are expected to rise in the next few years. before there were cases in which it could not offer the possibility of implanting a defibrillator a patient heart, if it necessarily had to undergo regular MRIs for a neurological disease or tumor. Fortunately, with new systems our company Ilesto is no longer necessary to consider these commitments”, Beatriz Fontán, Director of Marketing of Biotronik Spain advises.

implantable defibrillator re-timer Ilesto 7 HF-T of Biotronik.

The supervision of the State of the device and the patient’s health is accomplished with the BIOTRONIK Home Monitoring ® technology, which is compatible with DAI Ilesto 7 HF-T, the only system of telemonitoring has been approved in Europe and the United States.UU. for the early detection of clinical complications. They are reported to the physician critical changes immediately, allowing a rapid intervention. “Timely intervention significantly reduces the risk of stroke and unwanted therapy management and helps to adapt to the needs of health care of the individual,” concludes Dr. Martínez.

About BIOTRONIK is & Co. KG

BIOTRONIK is one of the companies of major cardiovascular medical devices in the world, with millions of implanted devices, and is represented in more than 100 countries with a workforce of 5,600 workers throughout the world. Known for staying abreast of what is happening in the medical community, BIOTRONIK assesses the challenges that physicians face and provides the best solutions for all phases of care to the patient, from diagnosis and treatment to patient management. Quality, innovation and reliability define Biotronik and its growing success, provide confidence and peace of mind to physicians and their patients around the world.

–
Referencia:

(1) Roguin et al., Europace 2008, 10, 336-346

(2) Morgan Stanley, CIE, 1996-2009 market.